Ilya M. Rachman, the CEO and Chairman of Immix Biopharma, Inc., has made a significant move by acquiring additional shares of the company. This transaction, reported in a recent SEC filing, demonstrates Rachman's confidence in the future of Immix Biopharma.
The filing, dated November 20, 2026, reveals that Rachman purchased 1,408.45 shares at a price of $7.10 per share on November 18, 2026. Following this acquisition, Rachman now holds a total of 1,143,091.45 shares in the company.
Immix Biopharma, Inc. is classified within the pharmaceutical preparations industry, which often sees insider trading activity as a reflection of company performance and market potential. Rachman's recent purchase is part of a series of transactions that highlight his ongoing commitment to the company.
According to the filing, Rachman is not only a director but also holds the title of CEO, indicating his integral role in the company’s operations and strategic direction. The SEC filing is part of the regulatory requirements for insiders to disclose their stock transactions, ensuring transparency for investors and stakeholders.
As of now, Immix Biopharma continues to navigate the complexities of the pharmaceutical landscape, and Rachman's increased ownership stake may signal his positive outlook for the company’s future endeavors.
Details were not available in the SEC filing regarding any upcoming plans or initiatives from the company following this transaction.
Read Next
Cizzle Brands announces $15.15M public offering and Nasdaq uplisting
Morris Gabriel S reports share acquisition in Immix Biopharma
Crown PropTech Acquisitions Updates on Mkango Merger Plans
Beberman Perry S acquires 10,000 shares of preferred stock
Kaye Jack Harry Gifts 1.6 Million Shares of Davion Healthcare
Filana Therapeutics CEO Increases Stake with Share Purchase







